GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Institutional Ownership

Entheon Biomedical (XCNQ:ENBI) Institutional Ownership : 0.07% (As of Jun. 04, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Entheon Biomedical's institutional ownership is 0.07%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Entheon Biomedical's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Entheon Biomedical's Float Percentage Of Total Shares Outstanding is 0.00%.


Entheon Biomedical Institutional Ownership Historical Data

The historical data trend for Entheon Biomedical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Institutional Ownership Chart

Entheon Biomedical Historical Data

The historical data trend for Entheon Biomedical can be seen below:

2022-05-31 2022-06-30 2022-07-31 2022-08-31 2022-09-30 2022-10-31 2022-11-30 2022-12-31 2023-01-31 2023-02-28
Institutional Ownership 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07

Entheon Biomedical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.
Executives
Brian Jahns Senior Officer

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines